Risk assessment in Kidney Transplantation.

XM-ONE® crossmatching provides information on presence of non-HLA antibodies compared to the currently used lymphocyte crossmatch tests.

XM-ONE® Multicenter study

The study showed that the XM-ONE® test can detect an antibody population not possible to detect with lymphocyte crossmatch tests that is strongly associated with rejection episodes and reduced kidney function after transplantation. The authors suggests that the XM-ONE® crossmatch test can identify patients at risk of antibody-mediated rejections.

Instructions for use


Product information and documents

Product information and documents (Instructions for use, Certificate of Analysis, etc.)

Go to Product Information

Sales & order

Go to Sales and Order

Get more information on the Sales & order.

Go to Sales & order

Clinical data

Go to Clinical data

Get more information on the Clinical data.

Go to Clinical data


Go to Downloads

Get more information on the Downloads.

Go to Downloads